Patents by Inventor Jose William Saldanha

Jose William Saldanha has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Humanized Antibodies That Recognize Alpha-Synuclein
    Publication number: 20220411486
    Abstract: The present application discloses humanized 9E4 antibodies. The antibodies bind to human alpha synuclein and can be used for immunotherapy of Lewy body disease.
    Type: Application
    Filed: April 26, 2022
    Publication date: December 29, 2022
    Inventors: Jose William Saldanha, Tarlochan S. Nijjar
  • Humanized antibodies that recognize alpha-synuclein
    Patent number: 11345749
    Abstract: The present application discloses humanized 9E4 antibodies. The antibodies bind to human alpha synuclein and can be used for immunotherapy of Lewy body disease.
    Type: Grant
    Filed: June 16, 2020
    Date of Patent: May 31, 2022
    Assignee: PROTHENA BIOSCIENCES LIMITED
    Inventors: Jose William Saldanha, Tarlochan S. Nijjar
  • Humanized Antibodies That Recognize Alpha-Synuclein
    Publication number: 20210040188
    Abstract: The present application discloses humanized 9E4 antibodies. The antibodies bind to human alpha synuclein and can be used for immunotherapy of Lewy body disease.
    Type: Application
    Filed: June 16, 2020
    Publication date: February 11, 2021
    Applicant: Prothena Biosciences Limited
    Inventors: Jose William Saldanha, Tarlochan S. Nijjar
  • Humanized antibodies that recognize alpha-synuclein
    Patent number: 10723792
    Abstract: The present application discloses humanized 9E4 antibodies. The antibodies bind to human alpha synuclein and can be used for immunotherapy of Lewy body disease.
    Type: Grant
    Filed: May 20, 2019
    Date of Patent: July 28, 2020
    Assignee: PROTHENA BIOSCIENCES LIMITED
    Inventors: Jose William Saldanha, Tarlochan S. Nijjar
  • Humanized Antibodies That Recognize Alpha-Synuclein
    Publication number: 20200024336
    Abstract: The present application discloses humanized 9E4 antibodies. The antibodies bind to human alpha synuclein and can be used for immunotherapy of Lewy body disease.
    Type: Application
    Filed: May 20, 2019
    Publication date: January 23, 2020
    Applicant: PROTHENA BIOSCIENCES LIMITED
    Inventors: Jose William Saldanha, Tarlochan S. Nijjar
  • Humanized antibodies that recognize alpha-synuclein
    Patent number: 10450369
    Abstract: The present application discloses humanized 9E4 antibodies. The antibodies bind to human alpha synuclein and can be used for immunotherapy of Lewy body disease.
    Type: Grant
    Filed: December 28, 2017
    Date of Patent: October 22, 2019
    Assignee: PROTHENA BIOSCIENCES LIMITED
    Inventors: Jose William Saldanha, Tarlochan S. Nijjar
  • Antibodies to VLA-1
    Patent number: 10336826
    Abstract: Antibodies that specifically bind to VLA-1 integrin and methods of using these antibodies to treat immunological disorders in a subject. Also included are crystal structures of complexes formed by VLA-1 antibodies and their ligands, and VLA-1 antagonists and agonists identified by using the structure coordinates of these structures.
    Type: Grant
    Filed: March 27, 2017
    Date of Patent: July 2, 2019
    Assignee: Biogen MA Inc.
    Inventors: Michael Karpusas, Paul D. Lyne, Ellen A. Garber Stark, Jose William Saldanha
  • Humanized Antibodies That Recognize Alpha-Synuclein
    Publication number: 20180201669
    Abstract: The present application discloses humanized 9E4 antibodies. The antibodies bind to human alpha synuclein and can be used for immunotherapy of Lewy body disease.
    Type: Application
    Filed: December 28, 2017
    Publication date: July 19, 2018
    Inventors: Jose William Saldanha, Tarlochan S. Nijjar
  • Humanized antibodies that recognize alpha-synuclein
    Patent number: 9884906
    Abstract: The present application discloses humanized 9E4 antibodies. The antibodies bind to human alpha synuclein and can be used for immunotherapy of Lewy body disease.
    Type: Grant
    Filed: December 21, 2016
    Date of Patent: February 6, 2018
    Assignee: PROTHENA BIOSCIENCES LIMITED
    Inventors: Jose William Saldanha, Tarlochan S. Nijjar
  • ANTIBODIES TO VLA-1
    Publication number: 20170335000
    Abstract: Antibodies that specifically bind to VLA-1 integrin and methods of using these antibodies to treat immunological disorders in a subject. Also included are crystal structures of complexes formed by VLA-1 antibodies and their ligands, and VLA-1 antagonists and agonists identified by using the structure coordinates of these structures.
    Type: Application
    Filed: March 27, 2017
    Publication date: November 23, 2017
    Applicant: BIOGEN MA INC.
    Inventors: Michael Karpusas, Paul D. Lyne, Ellen A. Garber Stark, Jose William Saldanha
  • Humanized Antibodies That Recognize Alpha-Synuclein
    Publication number: 20170240621
    Abstract: The present application discloses humanized 9E4 antibodies. The antibodies bind to human alpha synuclein and can be used for immunotherapy of Lewy body disease.
    Type: Application
    Filed: December 21, 2016
    Publication date: August 24, 2017
    Inventors: Jose William Saldanha, Tarlochan S. Nijjar
  • Antibodies to VLA-1
    Patent number: 9644030
    Abstract: Antibodies that specifically bind to VLA-1 integrin and methods of using these antibodies to treat immunological disorders in a subject. Also included are crystal structures of complexes formed by VLA-1 antibodies and their ligands, and VLA-1 antagonists and agonists identified by using the structure coordinates of these structures.
    Type: Grant
    Filed: January 15, 2015
    Date of Patent: May 9, 2017
    Assignee: BIOGEN MA INC.
    Inventors: Michael Karpusas, Paul D. Lyne, Ellen A. Garber Stark, Jose William Saldanha
  • Humanized antibodies that recognize alpha-synuclein
    Patent number: 9556259
    Abstract: The present application discloses humanized 9E4 antibodies. The antibodies bind to human alpha synuclein and can be used for immunotherapy of Lewy body disease.
    Type: Grant
    Filed: January 15, 2014
    Date of Patent: January 31, 2017
    Assignee: PROTHENA BIOSCIENCES LIMITED
    Inventors: José William Saldanha, Tarlochan S. Nijjar
  • ANTIBODIES TO VLA-1
    Publication number: 20150299323
    Abstract: Antibodies that specifically bind to VLA-1 integrin and methods of using these antibodies to treat immunological disorders in a subject. Also included are crystal structures of complexes formed by VLA-1 antibodies and their ligands, and VLA-1 antagonists and agonists identified by using the structure coordinates of these structures.
    Type: Application
    Filed: January 15, 2015
    Publication date: October 22, 2015
    Applicant: BIOGEN MA INC.
    Inventors: Michael Karpusas, Paul D. Lyne, Ellen A. Garber Stark, Jose William Saldanha
  • Humanized antibodies that recognize beta amyloid peptide
    Patent number: 9051363
    Abstract: The invention provides improved agents and methods for treatment of diseases associated with amyloid deposits of A? in the brain of a patient. Preferred agents include humanized antibodies.
    Type: Grant
    Filed: August 20, 2007
    Date of Patent: June 9, 2015
    Assignees: JANSSEN SCIENCES IRELAND UC, WYETH LLC
    Inventors: Guriq Basi, Jose William Saldanha, Dale B. Schenk
  • Humanized Antibodies That Recognize Alpha-Synuclein
    Publication number: 20140275495
    Abstract: The present application discloses humanized 9E4 antibodies. The antibodies bind to human alpha synuclein and can be used for immunotherapy of Lewy body disease.
    Type: Application
    Filed: January 15, 2014
    Publication date: September 18, 2014
    Applicant: Neotope Biosciences Limited
    Inventors: José William Saldanha, Tarlochan S. Nijjar
  • ANTIBODIES TO VLA-1
    Publication number: 20120177638
    Abstract: Antibodies that specifically bind to VLA-1 integrin and methods of using these antibodies to treat immunological disorders in a subject. Also included are crystal structures of complexes formed by VLA-1 antibodies and their ligands, and VLA-1 antagonists and agonists identified by using the structure coordinates of these structures.
    Type: Application
    Filed: November 15, 2011
    Publication date: July 12, 2012
    Applicant: BIOGEN IDEC MA INC.
    Inventors: Michael Karpusas, Paul D. Lyne, Jose William Saldanha, Ellen A. Garber
  • Antibodies to VLA-1
    Patent number: 8084028
    Abstract: Antibodies that specifically bind to VLA-1 integrin and methods of using these antibodies to treat immunological disorders in a subject. Also included are crystal structures of complexes formed by VLA-1 antibodies and their ligands, and VLA-1 antagonists and agonists identified by using the structure coordinates of these structures.
    Type: Grant
    Filed: January 31, 2011
    Date of Patent: December 27, 2011
    Assignee: Biogen Idec MA Inc.
    Inventors: Michael Karpusas, Paul D. Lyne, Jose William Saldanha, Ellen A. Garber
  • Cripto binding molecules
    Patent number: 8021661
    Abstract: The invention pertains to humanized forms of an anti-CRIPTO antibody and portions thereof. In one embodiment, the variable regions of these antibodies or polypeptides comprising them (e.g., full-length antibodies or domain deleted antibodies) can be used to treat disorders, such as cancer.
    Type: Grant
    Filed: July 3, 2007
    Date of Patent: September 20, 2011
    Assignee: Biogen Idec MA Inc.
    Inventors: Scott Glaser, Herman Van Vlijmen, Alexey Alexandrovich Lugovskoy, Michele Sanicola-Nadel, Xiufeng Wu, Ellen Garber, Jose William Saldanha
  • ANTIBODIES TO VLA-1
    Publication number: 20110189177
    Abstract: Antibodies that specifically bind to VLA-1 integrin and methods of using these antibodies to treat immunological disorders in a subject. Also included are crystal structures of complexes formed by VLA-1 antibodies and their ligands, and VLA-1 antagonists and agonists identified by using the structure coordinates of these structures.
    Type: Application
    Filed: January 31, 2011
    Publication date: August 4, 2011
    Applicant: BIOGEN IDEC MA INC.
    Inventors: Michael Karpusas, Paul D. Lyne, Jose William Saldanha, Ellen A. Garber